MARKET

JNJ

JNJ

Johnson & Johnson
NYSE
159.64
+3.36
+2.15%
Pre Market: 159.29 -0.35 -0.22% 08:09 07/26 EDT
OPEN
156.48
PREV CLOSE
156.28
HIGH
160.58
LOW
156.00
VOLUME
2.65K
TURNOVER
0
52 WEEK HIGH
175.97
52 WEEK LOW
141.57
MARKET CAP
384.20B
P/E (TTM)
10.54
1D
5D
1M
3M
1Y
5Y
1D
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Seeking Alpha · 6h ago
Top 10 Dividend Stocks For A Recession-Focused Portfolio In 2024
In times of uncertainty, constructing a recession-proof portfolio can help you to reduce the volatility of your investment portfolio. I have selected 10 companies that are suitable for such a portfolio. The companies have a robust business model, strong competitive advantages, and are financially healthy. Each of the selected companies offers a sustainable dividend. PepsiCo, Visa, Apple and McDonald's are among the top 10 dividend stocks for a Recession-Focused Portfolio in 2024.
Seeking Alpha · 8h ago
Courts, Congress Likely To Stand In Way Of J&J's Third Texas Two-Step Plan; U.S. Court Of Appeals For 3rd Circuit Latest To Reject Unprecedented Bankruptcy Strategy; Lawyers On Behalf Of Ovarian Cancer Victims Are Calling On Johnson & Johnson To End Its "War Of Attrition Against Cancer Victims."
Lawyers on behalf of ovarian cancer victims call on Johnson & Johnson to end its "war of attrition against cancer victims" The company has tried to stymie lawsuits by filing for bankruptcy. A U.S. Court of appeals ruled J&J can't stash its talc liabilities in a shell subsidiary and then file for bankruptcy to avoid lawsuits.
Benzinga · 12h ago
Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan
Lawyers on behalf of ovarian cancer victims are calling on Johnson & Johnson to end its “war of attrition against cancer victims.” The third time will not be the charm for J&J in its attempt to use bankruptcy to stymie thousands of lawsuits. The deadline for talc claimants to approve or reject a third bankruptcy attempt is Friday July 26.
Barchart · 17h ago
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
Today at 5pm ET is the final deadline for tens of thousands of ovarian cancer victims to vote on the approximately $8 billion Johnson & Johnson talcum powder settlement. The plan will compensate current and future claimants who were harmed by J&J’s talc powder products. Under the plan, ovarian cancer claimants are expected to receive an average of $75,000 to $150,000 each. Talc claimants canVote on the plan at www.OfficialTalcClaims.com.
Barchart · 18h ago
J&J talc bankruptcy plan appeal denied
Seeking Alpha · 23h ago
3 Stocks Reeling From Ruined Reputations: Can They Recover?
Investorplace · 1d ago
IBM, Salesforce share gains contribute to Dow's nearly 350-point jump
MarketWatch · 1d ago
More
About JNJ
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).

Webull offers Johnson & Johnson stock information, including NYSE: JNJ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JNJ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JNJ stock methods without spending real money on the virtual paper trading platform.